86386-73-4 | Fluconazole (C₁₃H₁₂F₂N₆O)

Chemical type

• Triazole antifungal

^[1]

• Antifungal agent
• Moderate CYP3A4 inhibitor

^[2]

Key properties

• Inhibits fungal ergosterol synthesis; broad-spectrum activity against Candida species

^[1]

• Increases plasma concentrations of CYP3A4-metabolized drugs
• Administered as loading dose (400 mg) followed by maintenance (200 mg QD)
• Well-known for drug-drug interactions with CYP3A substrates

^[2]

• Prevention or treatment of fungal infections; part of supportive therapy to manage potential infections in SJS patient

^[1]

• Antifungal treatment
• Inhibitor of CYP3A4 to study pharmacokinetic interactions

^[2]

Classification by use

• Antifungal agents for infection control
• Drugs for supportive care in hypersensitivity

^[1]

• Antifungal drugs
• CYP enzyme inhibitors
• Pharmacokinetic interaction probes

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Stevens-Johnson syndrome triggered by phenytoin in a patient with type 2 diabetes and seizures, Exploratory Research in Clinical and Social Pharmacy, Volume 19, September 2025, 100624
2. [Cite:2] Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects, European Journal of Pharmaceutical Sciences, Volume 212, 1 September 2025, 107163